TD Cowen raised the firm’s price target on GeneDx (WGS) to $135 from $118 and keeps a Buy rating on the shares. The firm said they provided solid guidance but a focus in 2025 will be both driving more utilization in the top indications with developmental delay and autism, while starting to push in new disease areas such as cerebral palsy and hearing loss.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Reports Strong 2024 Growth and 2025 Outlook
- GeneDx Holdings: Strong Buy Rating Backed by Impressive Q4 Results and 2025 Growth Potential
- GeneDx Highlights Strong Growth in Earnings Call
- GeneDx Holdings: Strong Q4 Performance and Strategic Growth Justify Buy Rating
- GeneDx price target raised to $115 from $95 at BTIG